Company Analysis Moderna
1. Summary
Advantages
- Price (32.75 $) is less than fair price (41.26 $)
- The stock's return over the last year (22.8%) is higher than the sector average (-4.98%).
Disadvantages
- Dividends (0%) are below the sector average (0.5317%).
- Current debt level 5.28% has increased over 5 years from 2.82%.
- The company's current efficiency (ROE=-28.77%) is lower than the sector average (ROE=106.63%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Moderna | Healthcare | Index | |
|---|---|---|---|
| 7 days | -3.1% | -13.4% | -0.1% |
| 90 days | 22% | -1.6% | 2.1% |
| 1 year | 22.8% | -5% | 19.8% |
MRNA vs Sector: Moderna has outperformed the "Healthcare" sector by 27.77% over the past year.
MRNA vs Market: Moderna has outperformed the market by 2.99% over the past year.
Stable price: MRNA is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: MRNA with weekly volatility of 0.4384% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Below fair price: The current price (32.75 $) is lower than the fair price (41.26 $).
Price significantly below the fair price: The current price (32.75 $) is 26% lower than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-2.77) is lower than that of the sector as a whole (33.49).
P/E vs Market: The company's P/E (-2.77) is higher than that of the market as a whole (-68.72).
5.3. P/BV
P/BV vs Sector: The company's P/BV (1.39) is lower than that of the sector as a whole (260.15).
P/BV vs Market: The company's P/BV (1.39) is lower than that of the market as a whole (51.39).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (4.73) is lower than that of the sector as a whole (129.83).
P/S vs Market: The company's P/S indicator (4.73) is lower than that of the market as a whole (148.63).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-4.11) is higher than that of the sector as a whole (-28.84).
EV/Ebitda vs Market: The company's EV/Ebitda (-4.11) is higher than that of the market as a whole (-95.22).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -25.84% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-25.84%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-598.11%).
6.4. ROE
ROE vs Sector: The company's ROE (-28.77%) is lower than that of the sector as a whole (106.63%).
ROE vs Market: The company's ROE (-28.77%) is lower than that of the market as a whole (-6.23%).
6.6. ROA
ROA vs Sector: The company's ROA (-21.87%) is lower than that of the sector as a whole (-2.32%).
ROA vs Market: The company's ROA (-21.87%) is lower than that of the market as a whole (38.59%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (131.22%) is higher than that of the sector as a whole (0.8343%).
ROIC vs Market: The company's ROIC (131.22%) is higher than that of the market as a whole (9.66%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5317%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
9. Insider trades
9.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
9.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 11.06.2025 | Hussain Abbas Director |
Sale | 28 | 8 736 | 312 |
| 09.12.2024 | Klinger Shannon Thyme Officer |
Purchase | 44.68 | 23 636 | 529 |
| 03.12.2024 | Hoge Stephen Officer |
Purchase | 43.3 | 13 596 | 314 |
| 09.09.2024 | Klinger Shannon Thyme Chief Legal Officer |
Sale | 73.57 | 40 537 | 551 |
| 15.07.2024 | Hoge Stephen President |
Sale | 121.12 | 1 816 800 | 15 000 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
